Filing Details
- Accession Number:
- 0001209191-18-008224
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2018-02-07 18:16:30
- Reporting Period:
- 2018-02-05
- Accepted Time:
- 2018-02-07 18:16:30
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 875320 | Vertex Pharmaceuticals Inc / Ma | VRTX | Pharmaceutical Preparations (2834) | 043039129 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1610876 | Jeffrey Chodakewitz | C/O Vertex Pharmaceuticals Incorporated 50 Northern Avenue Boston MA 02210 | Evp Gmda, Cmo | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2018-02-05 | 3,594 | $109.14 | 56,118 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2018-02-05 | 494 | $158.32 | 55,624 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2018-02-05 | 700 | $159.62 | 54,924 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2018-02-05 | 500 | $160.50 | 54,424 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2018-02-05 | 500 | $161.51 | 53,924 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2018-02-05 | 400 | $162.94 | 53,524 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2018-02-05 | 900 | $164.12 | 52,624 | No | 4 | S | Direct | |
| Common Stock | Disposition | 2018-02-05 | 100 | $164.71 | 52,524 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Stock Option (Right to Buy) | Disposition | 2018-02-05 | 3,594 | $0.00 | 3,594 | $109.14 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 14,375 | 2025-02-02 | No | 4 | M | Direct |
Footnotes
- Transaction made pursuant to Dr. Chodakewitz's company-approved trading plan under Rule 10b5-1.
- Open market sales reported on this line occurred at a weighted average price of $158.32 (range $158.01 to $158.82).
- Dr. Chodakewitz undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
- Open market sales reported on this line occurred at a weighted average price of $159.62 (range $159.18 to $160.06).
- Open market sales reported on this line occurred at a weighted average price of $160.50 (range $160.20 to $160.86).
- Open market sales reported on this line occurred at a weighted average price of $161.51 (range $161.32 to $161.85).
- Open market sales reported on this line occurred at a weighted average price of $162.94 (range $162.52 to $163.40).
- Open market sales reported on this line occurred at a weighted average price of $164.12 (range $163.65 to $164.53).
- The option vests in 16 quarterly installments from 2/3/2015.
Billionaire Hedge Funds
